|
Items in cart [0] |
Questions? Call 888-624-8373 |
HARDBACK + PDF HARDBACK PDF BOOK PDF CHAPTERS Free Resources |
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. G Garlic, 262 Gastroenterological disease, 45 Geriatric medicine, 242–244, 248–249 Germany, 264–265 Ginkgo biloba, 21 H Headache treatment, 38 cost-effectiveness of CAM, 49–50 Health food stores, 59–60 Cochrane Library data, 133 patterns of use, 35, 44, 48, 254 pharmacist education in, 227 sources of information about, 58–59 See also Dietary supplements Holistic care, 211 Homeless people, 42 attitudes of conventional physicians, 203 insurance coverage, 47 licensure for, 238 N-of-1 research studies, 112 Hypericum. See St. John’s wort I Indinavir, 23 Informed consent, 177–178, 181, 183 patient preference for CAM therapy in absence of proof of effect, 184–188 Institute of Medicine, 29–31, 270–271 Insurance. See Reimbursement Integration of CAM and conventional medicine, x CAM-centric services model, 218 CAM training in medical schools, 17, 226–227, 230–237, 248 cancer treatment, 202 complementary services model, 218 conceptualization of health in, 210–211 concierge model, 219 consultant model, 217 consumer demand and, 208–209 continuity of care concerns, 219 ethical and legal considerations, 8, 179–192 financial considerations, 218, 219–220 fitness center model, 217 implementation models, 217–220 in institutions, 201–202, 208, 215–217 integrative medical doctor/DO-centric service model, 218 motivation of health care practitioners for, 208–209, 218 NCCAM efforts, 25 patient oriented delivery system, 219 patient–physician relationship in, 209, 210 patient preference for CAM therapy in absence of proof of effect, 184–188, 214–215 physician characteristics and, 209 primary-care model, 217 recognition of medical pluralism in, 169–171 recommendations for research, 7–8, 221–222 reimbursement patterns, 206–208 spectrum model, 210 trends, 6–7, 196, 201–206, 278 virtual model, 217 See also Translating research findings into practice International Ethical Guidelines for Biomedical Research Involving Human Subjects , 174–175 Isoflavone formononetin, 147 J Journal of the American Medical Association, 21 K Knowledge-based medicine, 15
|
|
|||||||||||||||
